Table 1.
Baseline demographic and laboratory measurements by treatment allocation
| Simvastatin plus ezetimibe (n = 4650) | Placebo (n = 4620) | |
|---|---|---|
| Demographics | ||
| Age at randomization (years)a | 62 (12) | 62 (12) |
| Men | 2915 (63%) | 2885 (62%) |
| Ethnicity | ||
| White | 3332 (72%) | 3314 (72%) |
| Black | 137 (3%) | 127 (3%) |
| Chinese | 557 (12%) | 563 (12%) |
| Other Asian | 486 (10%) | 480 (10%) |
| Other/not specified | 138 (3%) | 136 (3%) |
| Prior disease | ||
| Prior vascular diseasea | 711 (15%) | 682 (15%) |
| Diabetesa | 1054 (23%) | 1040 (23%) |
| Renal status | ||
| On dialysisa | 1534 (33%) | 1491 (32%) |
| Haemodialysis | 1275 (27%) | 1253 (27%) |
| Peritoneal dialysis | 259 (6%) | 238 (5%) |
| Not on dialysisa | 3116 (67%) | 3129 (68%) |
| Baseline measurements | ||
| Total cholesterol (mmol/L)a | 4.88 (1.20) | 4.90 (1.17) |
| LDL cholesterol (mmol/L)a | 2.77 (0.88) | 2.78 (0.87) |
| HDL cholesterol (mmol/L)a | 1.12 (0.35) | 1.11 (0.34) |
| Triglycerides (mmol/L)a | 2.31 (1.76) | 2.34 (1.68) |
| Body mass index (kg/m2)a | 27.1 (5.7) | 27.1 (5.6) |
| Renal function | ||
| MDRD-estimated GFR (mL/min/1.73 m2)a,b,c | 26.6 (12.9) | 26.6 (13.1) |
| ≥60 | 44 (1%) | 44 (1%) |
| ≥30 to <60 | 1100 (37%) | 1055 (35%) |
| ≥15 to <30 | 1246 (41%) | 1319 (44%) |
| < 15 | 613 (20%) | 606 (20%) |
| Not available | 113 | 105 |
Data are n (%) or mean (SD)
MDRD Modified Diet in Renal Disease, GFR glomerular filtration rate
aVariables updated at 1 year for patients originally allocated simvastatin only who were rerandomized to simvastatin plus ezetimibe or placebo
bPercentages exclude participants for whom data were not available for that category
cFor patients not on dialysis